Drugs / SynKIR-310
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06544265 | Nov 2024 → Sep 2028 expected | T-cell/histiocyte rich large B cell lymphoma, Waldenstrom macroglobulinemia, diffuse large B-cell lymphoma with chronic inflammation, follicular lymphoma +6 | Verismo Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SynKIR-310 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06544265 ↗ |
| Modality | Cell therapy | “Autologous T Cells transduced with CD19 KIR-CAR” NCT06544265 ↗ |
| Route | Intravenous | “single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL” NCT06544265 ↗ |